A 58-year-old man with type 2 diabetes is told his estimated GFR has dropped into the mid-50s — stage 3 chronic kidney disease. His nephrologist starts him on an ACE inhibitor and tightens his glucose control. Then a question comes up at his next endocrinology visit: should he be on a GLP-1? For years, the answer for patients with significant kidney disease was hesitation — concerns about dehydration, contrast risk, and uncertainty about long-term renal effects. As of 2024, that conversation has changed. The FLOW trial, published in The New England Journal of Medicine, showed that semaglutide reduced major kidney events by 24% in patients with type 2 diabetes and chronic kidney disease. The trial was stopped early for efficacy. The FDA expanded Ozempic’s label to include reducing the risk of kidney disease worsening in this population. For patients with diabetic kidney disease, the GLP-1 conversation now starts in a different place.
This is post #5 in our series, The GLP-1 Benefits Nobody’s Talking About — See the Full Guide →
What the FLOW Trial Actually Tested
The FLOW trial (Evaluation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes) enrolled 3,533 adults with type 2 diabetes and chronic kidney disease across 28 countries. Participants had an estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73m² and elevated urine albumin-to-creatinine ratios — the standard markers of established CKD. They were randomized to semaglutide 1.0mg weekly or placebo, on top of standard kidney care including ACE inhibitors or ARBs and, where appropriate, SGLT2 inhibitors.
The primary outcome was a composite of five major kidney events: kidney failure (initiation of dialysis or kidney transplant), at least 50% reduction in eGFR from baseline, kidney-related death, cardiovascular death, or sustained eGFR below 15. Semaglutide reduced this composite outcome by 24% versus placebo (hazard ratio 0.76, 95% CI 0.66-0.88, p<0.001).
Why the Trial Was Stopped Early
FLOW was originally designed to run longer, but in October 2023 the independent data monitoring committee recommended ending it at the planned interim analysis. The reason: the kidney benefit was already so clear that continuing the placebo arm could no longer be justified. According to industry reporting on the early stop, this kind of decision — halting for efficacy rather than safety — is uncommon. It signals not just statistical significance but clinical magnitude.
Beyond the primary kidney composite, FLOW also showed reductions in cardiovascular events and all-cause mortality in this population. That alignment matters because patients with diabetic kidney disease die from cardiovascular causes at substantially higher rates than the general population — a benefit that addresses both the kidney and the heart in the same intervention is meaningful in this group.
How a GLP-1 Helps the Kidneys
The mechanisms appear to be multiple. Tighter glucose control protects the glomerular filtration apparatus from sustained hyperglycemic injury. Reduced systemic inflammation, including markers like high-sensitivity C-reactive protein, contributes to slower CKD progression. GLP-1s also produce modest reductions in systolic blood pressure, which directly reduces glomerular hypertension — one of the central drivers of progressive kidney damage in diabetes.
There may also be more direct renal effects. Animal and translational research suggests GLP-1 receptors are expressed in kidney tissue and that activation may affect renal hemodynamics, sodium handling, and oxidative stress in ways that go beyond what blood pressure or glucose alone explain. The National Kidney Foundation’s coverage of the FDA approval emphasizes that the findings broaden the toolkit for slowing CKD progression in diabetes — alongside ACE inhibitors, ARBs, and SGLT2 inhibitors, GLP-1s now have outcome trial data supporting their role in this specific patient population.
Regulatory Status: What This Approval Does and Doesn’t Cover
In January 2025, the FDA approved an expanded indication for Ozempic (semaglutide 1.0mg from Novo Nordisk): reducing the risk of sustained eGFR decline, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. This was the first FDA approval of a GLP-1 for a kidney-specific indication, based directly on the FLOW trial. Per the FDA’s approval letter, the indication requires both type 2 diabetes AND established CKD — not one or the other.
Two distinctions need to be stated as clearly as the cardiovascular post does for the SELECT trial. Semaglutide (Ozempic) is FDA-approved for kidney protection only in adults with type 2 diabetes AND chronic kidney disease — this is the branded Ozempic 1.0mg product from Novo Nordisk that completed the full FDA drug approval process. Compounded semaglutide is NOT FDA-approved for any indication, including kidney protection. The compounded formulation contains the same active molecule but has not undergone the FDA’s safety and efficacy review for any specific use. Compounded medications are prepared by licensed compounding pharmacies under physician supervision. They are not FDA-approved products.
Critical compliance distinction: The FDA kidney approval is for branded Ozempic (semaglutide 1.0mg from Novo Nordisk) in adults with type 2 diabetes AND established CKD. Compounded semaglutide is NOT FDA-approved for this or any indication. Tirzepatide (Mounjaro/Zepbound) does NOT have FDA approval for kidney protection — ongoing studies are evaluating its renal effects, but the outcome data is not yet at the level required for an FDA kidney indication.
None of this information should be used to conclude that compounded semaglutide treats kidney disease or that starting a GLP-1 is a substitute for nephrology care.
Who This Applies To — And Who It Doesn’t
FLOW enrolled patients with both type 2 diabetes and chronic kidney disease. The 24% reduction applies to that specific population. It does not directly apply to patients with diabetes alone and normal kidney function. It does not apply to patients with kidney disease without diabetes — for example, those whose CKD is from polycystic kidney disease, hypertensive nephrosclerosis, or other non-diabetic causes. And it does not apply to patients without CKD who are taking a GLP-1 for weight management.
The data also speaks specifically to patients on standard kidney care: ACE inhibitors or ARBs, optimized blood pressure management, and where indicated, SGLT2 inhibitors. The 24% reduction was on top of those medications, not in place of them. Any patient with diabetic kidney disease considering semaglutide for kidney protection should be doing so in collaboration with their nephrologist or endocrinologist — not as a self-directed addition to weight management.
The Critical Caveats
This is the section that matters most, and it deserves to be read carefully before any other part of this article is shared or acted on.
FLOW does not mean every GLP-1 protects every kidney
The FLOW trial tested semaglutide 1.0mg, the dose used for type 2 diabetes management — not the higher 2.4mg dose used for chronic weight management (Wegovy). It tested patients with diabetes AND CKD, not patients with isolated weight concerns. Generalizing the 24% number to a different patient population, a different dose, or a different molecule is not supported by the FLOW data.
Compounded semaglutide is NOT FDA-approved for kidney protection
The Ozempic kidney indication applies to the brand-name Novo Nordisk product. Compounded semaglutide is a different category of product: it contains the same active molecule but has not undergone FDA review for safety or efficacy for any indication. Compounded medications are prepared by licensed compounding pharmacies under physician supervision. They are not FDA-approved products. A patient who needs kidney protection should be discussing FDA-approved options with their nephrologist or endocrinologist — not assuming a compounded product confers the same benefit.
Tirzepatide does not yet have a kidney indication
Most SkinnyVIP patients are on tirzepatide for weight management. Tirzepatide is a different molecule than semaglutide — a dual GIP/GLP-1 agonist rather than a pure GLP-1 agonist. Whether tirzepatide produces similar kidney protection is being studied, but the outcome data does not yet exist at the level FLOW provided for semaglutide. The FDA has not approved tirzepatide for kidney protection. This is a gap that may close in coming years — or may not. The data will determine that, not assumption.
A GLP-1 is not a replacement for nephrology care
FLOW participants were already on standard kidney care: ACE inhibitors or ARBs, blood pressure management, glycemic control, and where appropriate, SGLT2 inhibitors. The 24% additional risk reduction was on top of those treatments, not in place of them. A GLP-1 does not replace an ACE inhibitor. It does not replace an SGLT2 inhibitor. It does not replace the lifestyle modifications and monitoring that nephrology care provides. Anyone considering semaglutide specifically for kidney protection should be doing so under the care of the physician managing their CKD — not as a self-directed substitute for existing therapy.
This is not a reason to start a GLP-1 primarily to prevent kidney disease
FLOW enrolled patients with already-diagnosed type 2 diabetes and CKD in a carefully monitored clinical setting. Using FLOW as a reason to seek a GLP-1 prescription for kidney prevention — outside of an appropriate medical evaluation, in a patient without diabetes or CKD — is not how the evidence should be applied. The starting point is always a physician who can evaluate kidney function (eGFR and albuminuria), assess your full clinical picture, and determine whether an FDA-approved indication applies to your situation.
The Physician’s Perspective
In the words of Dr. SkinnyVIP: “FLOW is one of the most consequential GLP-1 trials of the last decade because it changes the conversation for a population that historically had limited options to slow CKD progression. But the part patients sometimes miss is the population. This was patients with diabetes AND chronic kidney disease, on standard kidney care, treated with FDA-approved branded semaglutide. The 24% number doesn’t transfer to a healthy adult on a compounded GLP-1 for weight loss. It transfers to a specific patient phenotype, and the answer for everyone else — including most SkinnyVIP patients — is to understand the science and discuss your individual kidney profile with your physician. Compounded medications are prepared by licensed compounding pharmacies under physician supervision. They are not FDA-approved products. That distinction is the foundation of an honest conversation about what your medication is and isn’t approved to do.”
The Bottom Line
Three things are true about FLOW and its implications, and all three need to be held together.
First: FLOW showed a real, clinically meaningful 24% reduction in major kidney events — including kidney failure, sustained eGFR decline, and cardiovascular death — in patients with type 2 diabetes and chronic kidney disease who were treated with semaglutide on top of standard kidney care. This was a large, rigorous, randomized, placebo-controlled trial published in the New England Journal of Medicine. The trial was stopped early for efficacy. The finding is solid.
Second: The FDA kidney approval is for branded Ozempic (semaglutide 1.0mg from Novo Nordisk) in adults with type 2 diabetes AND established CKD. That approval is not for compounded semaglutide — which is NOT FDA-approved for any indication, including kidney protection. It is not for tirzepatide, which does not have FDA approval for any kidney indication. And it is not for patients without diabetes or without CKD.
Third: For most SkinnyVIP patients on compounded medications for weight management, the FLOW data is important background information — not a clinical recommendation. If you have type 2 diabetes and chronic kidney disease, the most important next step is discussing your full medication regimen with your nephrologist or endocrinologist. If you don’t have those conditions, FLOW is part of a larger picture of why GLP-1s are turning out to do more than weight loss — but it’s not a reason to assume your weight management medication is also protecting your kidneys.
Disclaimer: This content is for informational purposes only and is not medical advice. Results vary. Semaglutide (Ozempic) is FDA-approved to reduce the risk of kidney disease worsening, kidney failure, and cardiovascular death only in adults with type 2 diabetes and chronic kidney disease — based on the January 2025 FDA approval. Compounded semaglutide is NOT FDA-approved for any indication, including kidney protection. Tirzepatide does NOT have FDA approval for kidney protection. Compounded medications are prepared by licensed compounding pharmacies under physician supervision. They are not FDA-approved products. Always consult with a licensed physician before starting or changing any medication, and discuss kidney function with the nephrologist or endocrinologist managing your CKD.